Interleukin-1β, interleukin-6, and interleukin-17A as indicators reflecting clinical response to celecoxib in ankylosing spondylitis patients

Zhang, Yang; Ning, Chao; Zhou, Huijie; Yan, Yingjie; Liu, Fulai; Huang, Yayun

doi:10.1007/s11845-020-02366-5

Cited by 6 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Then store the serum samples at − 80 °C. The levels of caspase-1, interleukin-1β (IL-1β), interleukin-17A (IL-17A), interleukin-18 (IL-18), and interleukin-23 (IL-23) were measured using the following ELISA kits: caspase-1 ELISA kit (EH70RB, human, Thermo Fisher), caspase-1 ELISA kit (kt21346, mouse, MSK), IL-1β ELISA kit (kt98060, human, MSK), IL-1β ELISA kit (kt21178, mouse, MSK), IL-17A ELISA kit (kt99222, human, MSK), IL-17A ELISA kit (kt21287, mouse, MSK), IL-18 ELISA kit (kt98065, human, MSK), IL-18 ELISA kit (kt21183, mouse, MSK), IL-23 ELISA kit (kt98055, human, MSK), and IL-23 ELISA kit (kt21102, mouse, MSK) [ 31 ].…”

Section: Methodsmentioning

confidence: 99%

Molecular mechanisms of AMPK/YAP/NLRP3 signaling pathway affecting the occurrence and development of ankylosing spondylitis

Fu,

Guo,

Pan

et al. 2023

J Orthop Surg Res

View full text Add to dashboard Cite

Background Investigate the AMPK (protein kinase AMP-activated catalytic subunit alpha 1)/YAP (Yes1 associated transcriptional regulator)/NLRP3 (NLR family pyrin domain containing 3) signaling pathway's role in ankylosing spondylitis (AS) development using public database analysis, in vitro and in vivo experiments. Methods Retrieve AS dataset, analyze differential gene expression in R, conduct functional enrichment analysis, collect 30 AS patient and 30 normal control samples, and construct a mouse model. ELISA, IP, and knockdown experiments were performed to detect expression changes. Results NLRP3 was identified as a significant AS-related gene. Caspase-1, IL-1β, IL-17A, IL-18, IL-23, YAP, and NLRP3 were upregulated in AS patients. Overexpressing AMPK inhibited YAP's blockade on NLRP3 ubiquitination, reducing ossification in fibroblasts. Inhibiting AMPK exacerbated AS symptoms in AS mice. Conclusion AMPK may suppress YAP expression, leading to NLRP3 inflammasome inhibition and AS alleviation.

show abstract

Section: Methodsmentioning

confidence: 99%

Molecular mechanisms of AMPK/YAP/NLRP3 signaling pathway affecting the occurrence and development of ankylosing spondylitis

Fu,

Guo,

Pan

et al. 2023

J Orthop Surg Res

View full text Add to dashboard Cite

show abstract

“…Co-expression associations of RBPs and targeted genes were built by the "grn" algorithm from the SCENIC python workflow (version 1.12) using default parameters. 1 Networks of the modules with RBPs and their target genes were visualized by Cytoscape (v3.9.1). analyzed.…”

Section: Rna-binding Protein Regulatory Program Analysismentioning

confidence: 99%

“…Ankylosing spondylitis (AS) is an inflammatory rheumatic disease that affects the axial bones and joints and is characterized by abnormal immune response and bone remodeling ( 1 , 2 ). The prevalence rate is 0.09%–0.3% ( 3 , 4 ).…”

Section: Introductionmentioning

confidence: 99%

Single-cell transcriptome revealed dysregulated RNA-binding protein expression patterns and functions in human ankylosing spondylitis

Ren,

Li,

Wang

et al. 2024

Front. Med.

View full text Add to dashboard Cite

ObjectiveTo explore the expression characteristics and regulatory patterns of RBPs in different immune cell types of AS, and to clarify the potential key role of RBPs in the occurrence and development of AS disease.MethodsPBMC sample data from scRNA-seq (HC*29, AS*10) and bulk RNA-seq (NC*3, AS*5) were selected for correlation analysis.Results(1) Compared with the HC group, the numbers of B, DC (dendritic cells), CD14+ Mono and CD8+ T cells were increased in AS group, while the numbers of platelet (platelets), CD8+ NKT, CD16+ Mono (non-classical monocytes), Native CD4+ T and NK were decreased. (2) Through the analysis of RBP genes in B cells, some RBPs were found to play an important role in B cell differentiation and function, such as DDX3X, SFPQ, SRRM1, UPF2. (3) It may be related to B-cell receptor, IgA immunity, NOD-like receptor and other signaling pathways; Through the analysis of RBP genes in CD8+ T cells, some RBPs that play an important role in the immune regulation of CD8+ T were found, such as EIF2S3, EIF4B, HSPA5, MSL3, PABPC1 and SRSF7; It may be related to T cell receptor, TNF, IL17 and other signaling pathways. (4) Based on bulk RNA-seq, it was found that compared with HC and AS patients, differentially expressed variable splicing genes (RASGs) may play an important role in the occurrence and development of AS by participating in transcriptional regulation, protein phosphorylation and ubiquitination, DNA replication, angiogenesis, intracellular signal transduction and other related pathways.ConclusionRBPs has specific expression characteristics in different immune cell types of AS patients, and has important regulatory functions. Its abnormal expression and regulation may be closely related to the occurrence and development of AS.

show abstract

“…A possible mechanism, by which celecoxib improves these symptoms in individuals with autistic disorder is, again, the inhibition of microglial/monocyte [ 63 ] and/or Th17 cells activation [ 64 ]. Interestingly, several reports have suggested that different proinflammatory cytokines, such as IL-1β, IL-6, and/or IL-17A, could serve as indicators for predicting clinical response to celecoxib in individuals with immune-mediated conditions, such as ankylosing spondylitis [ 65 ].…”

Section: Summary Of Findingsmentioning

confidence: 99%

Immunoregulatory and/or Anti-inflammatory Agents for the Management of Core and Associated Symptoms in Individuals with Autism Spectrum Disorder: A Narrative Review of Randomized, Placebo-Controlled Trials

2023

View full text Add to dashboard Cite

Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental condition with a so far poorly understood underlying pathogenesis, and few effective therapies for core symptoms. Accumulating evidence supports an association between ASD and immune/inflammatory processes, arising as a possible pathway for new drug intervention. However, current literature on the efficacy of immunoregulatory/anti-inflammatory interventions on ASD symptoms is still limited. The aim of this narrative review was to summarize and discuss the latest evidence on the use of immunoregulatory and/or anti-inflammatory agents for the management of this condition. During the last 10 years, several randomized, placebo-controlled trials on the effectiveness of (add-on) treatment with prednisolone, pregnenolone, celecoxib, minocycline, N -acetylcysteine (NAC), sulforaphane (SFN), and/or omega-3 fatty acids have been performed. Overall, a beneficial effect of prednisolone, pregnenolone, celecoxib, and/or omega-3 fatty acids on several core symptoms, such as stereotyped behavior , was found. (Add-on) treatment with prednisolone, pregnenolone, celecoxib, minocycline, NAC, SFN, and/or omega-3 fatty acids was also associated with a significantly higher improvement in other symptoms, such as irritability , hyperactivity , and/or lethargy when compared with placebo. The mechanisms by which these agents exert their action and improve symptoms of ASD are not fully understood. Interestingly, studies have suggested that all these agents may suppress microglial/monocyte proinflammatory activation and also restore several immune cell imbalances (e.g., T regulatory/T helper-17 cell imbalances), decreasing the levels of proinflammatory cytokines, such as interleukin (IL)-6 and/or IL-17A, both in the blood and in the brain of individuals with ASD. Although encouraging, the performance of larger randomized placebo-controlled trials, including more homogeneous populations, dosages, and longer periods of follow-up, are urgently needed in order to confirm the findings and to provide stronger evidence.

show abstract

Interleukin-1β, interleukin-6, and interleukin-17A as indicators reflecting clinical response to celecoxib in ankylosing spondylitis patients

Cited by 6 publications

References 16 publications

Molecular mechanisms of AMPK/YAP/NLRP3 signaling pathway affecting the occurrence and development of ankylosing spondylitis

Molecular mechanisms of AMPK/YAP/NLRP3 signaling pathway affecting the occurrence and development of ankylosing spondylitis

Single-cell transcriptome revealed dysregulated RNA-binding protein expression patterns and functions in human ankylosing spondylitis

Immunoregulatory and/or Anti-inflammatory Agents for the Management of Core and Associated Symptoms in Individuals with Autism Spectrum Disorder: A Narrative Review of Randomized, Placebo-Controlled Trials

Contact Info

Product

Resources

About